XML 79 R68.htm IDEA: XBRL DOCUMENT v3.24.0.1
Revenue Recognition - Additional Information (Detail) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disaggregation of Revenue [Line Items]      
Revenue $ 638,764,000 $ 801,536,000 $ 670,534,000
Revenue Benchmark [Member]      
Disaggregation of Revenue [Line Items]      
Revenue 0 0  
Revenue Benchmark [Member] | Customer Concentration Risk [Member]      
Disaggregation of Revenue [Line Items]      
Revenue $ 0 $ 0  
Revenue Benchmark [Member] | Minimum [Member] | Customer Concentration Risk [Member]      
Disaggregation of Revenue [Line Items]      
Concentration Risk, Percentage 10.00% 10.00%  
Pfizer Inc.      
Disaggregation of Revenue [Line Items]      
Revenue     $ 68,300,000
Pfizer Inc. | Revenue Benchmark [Member] | Customer Concentration Risk [Member]      
Disaggregation of Revenue [Line Items]      
Concentration Risk, Percentage     10.00%
Pfizer Inc. | Revenue Benchmark [Member] | Minimum [Member] | Customer Concentration Risk [Member]      
Disaggregation of Revenue [Line Items]      
Concentration Risk, Percentage     10.00%